Comparative Pharmacology
Head-to-head clinical analysis: MIGRANAL versus WIGRAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIGRANAL versus WIGRAINE.
MIGRANAL vs WIGRAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MIGRANAL (dihydroergotamine mesylate) is an ergot alkaloid with agonist activity at serotonin 5-HT1D and 5-HT1B receptors, leading to vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission, thereby aborting migraine attacks.
WIGRAINE is a combination product containing ergotamine, a vasoconstrictor that acts as an agonist at serotonin (5-HT1B/1D) and alpha-adrenergic receptors, and caffeine, which enhances ergotamine absorption and provides additional vasoconstriction.
1 mg intramuscularly at onset of migraine headache; may repeat after 1 hour if needed. Maximum: 2 mg per day and 4 mg per week.
For acute migraine: 2 tablets (each containing ergotamine tartrate 1 mg and caffeine 100 mg) orally at onset, then 1 tablet every 30 minutes as needed, maximum 6 tablets per attack, maximum 10 tablets per week.
None Documented
None Documented
Terminal elimination half-life ranges from 7 to 10 hours (mean 8.5 hours). Prolonged in renal impairment.
Ergotamine: ~2-3 hours (terminal). Clinical context: short half-life necessitates frequent dosing for acute migraine relief.
Primarily hepatic metabolism followed by renal excretion. Approximately 10% excreted unchanged in urine; fecal excretion accounts for <1%.
Primarily hepatic metabolism; renal excretion of metabolites. ~90% urinary, ~10% fecal.
Category C
Category C
Ergot Alkaloid
Ergot Alkaloid